| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f484d686d9b742d57dbd5522b0a3ef65 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70514
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate |
2016-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfebd28ebe50e8dd2ddee447b7362dd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38a49935cfdd812d45c7e41acdb4d47a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2413955d43225602b8354ddcfd0c6eb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31c0724a92fd887fe0c8a6e4bb433b09 |
| publicationDate |
2016-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016312183-A1 |
| titleOfInvention |
Agents and methods to elicit anti-tumor immune response |
| abstract |
The invention provides an isolated, purified population of human cells comprising CD8 + T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8 + T cells, (b) reducing Cbl-b activity in the CD8 + T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8 + T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018156886-A1 |
| priorityDate |
2006-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |